The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.
Ludmila Prudkin
No relevant relationships to disclose
Claudia Aura
No relevant relationships to disclose
Jose Jimenez
No relevant relationships to disclose
Nerea Peiro
No relevant relationships to disclose
Debora Moreno
No relevant relationships to disclose
Paola Martinez
No relevant relationships to disclose
Gertrudis Sanchez
No relevant relationships to disclose
maria Del Carmen Diaz
No relevant relationships to disclose
Alejandra Iglesias
No relevant relationships to disclose
Maria Angeles Diaz
No relevant relationships to disclose
Ana Vivancos
No relevant relationships to disclose
Jordi Rodon
No relevant relationships to disclose
Javier Cortes
No relevant relationships to disclose
Ana Oaknin
No relevant relationships to disclose
Jose Maria Del Campo
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Josep Tabernero
No relevant relationships to disclose
Paolo Nuciforo
No relevant relationships to disclose